Back to Newsroom

Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering

BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $13.2 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Cyclacel.